Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics (CLDI) has shared an update.
Calidi Biotherapeutics, Inc. has settled with an investor through a series of agreements involving a $2.0 million and a $1.5 million convertible note, aiming to satisfy conditions from a previous business combination. These notes, due in 2028 with a 10% interest rate, offer the investor the option to convert the debt into shares at a discounted rate, with provisions for mandatory conversion under certain financing conditions. The settlement provides a mutual release of claims and amends previous agreements, streamlining the company’s financial and legal obligations.
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.